

Farbeyondz Pte Ltd
 128 Tuas South Ave 3
 #03-02
 Singapore 637370


The following sample was submitted and identified by the client as:

Sample Name : Beyondz Turmeric

Sample Receiving Date : 10 Jul 2023
 Date of Test/s Performed : 13 Jul 2023 to 27 Jul 2023

* * *

| Test Item | Test Method | Results | LOQ/LOD | Unit |
|--|---|--------------|---------|-------------|
| 365 Chemicals for clinical use | --- | --- | --- | --- |
| The sample is tested 365 Chemicals for clinical use (see appendix) | According to SGS Inhouse method (TESP-UB-0173, TESP-UB-0181, TESP-UB-0182). Analysis was performed by TLC, LC/MS/MS, or GC/MS | Not detected | --- | ppm(µg/ g) |



Signed for and on behalf of
 SGS Testing & Control Services Singapore Pte Ltd



Y C Tham (Ms)
 Technical Manager, Multi-Lab

This document is issued by the Company subject to its General Conditions of Service accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained here on reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 30 days only.

Appendix

365 Chemicals for Clinical Use Test Items & LOD List :

Unit:ppm(µg/g)

| Test Item | CAS NO. | 51-LOD | Test Item | CAS NO. | LOD |
|-------------------------------|-------------|---------------|----------------------------|-------------|----------------|
| 2,4-Dinitrophenol | 28-5 | 22348-3600 | Benzathine-penicillin | 41372-02-5 | 3300 |
| 2-Diphenylmethylpyrrolidine | 31-8 | 566-19-8-900 | Benzbromarone | 3562-84-3 | 144-900 |
| 7-keto-Dehydroepiandrosterone | 103-90-2 | 3000 | Benzhexol | 11-6 | 94-09-71800 |
| Acetaminophen | 147676-78-6 | 300 | Benzocaine | 642-72-8 | 378-300 |
| Acetil acid | 831217-01-7 | 1500 | Benzydamine | 44-9 | 987-24-6348 |
| Acetildenafil | 968-81-0 | 62-600 | Betamethasone | 22298-29-9 | 900 |
| Acetohexamide | 44-2 | 1261351-750 | Betamethasone 21 Acetate | 5593-20-4 | 4500 |
| Acetophenetidin | 28-3 | 1837-57-3600 | Betamethasone Benzoate | 2152-44-5 | 3225 |
| Acetylvardenafil | 6 | 315-30-0-600 | Betamethasone Dipropionate | 41859-67-0 | 1050 |
| Acrinol | 18683-91-5 | 2832 | Betamethasone Valerate | 603-50-9 | 108 |
| Allopurinol | 317-34-0 | 58-600 | Bezafibrate | 104344-23-2 | 600 |
| Ambroxol | 15-1 | 385769-600 | Bisacodyl | 3572-43-8 | 600 |
| Aminophylline | 84-6 | 549-18-8-4500 | Bisoprolol Fumarate | 4093-35-0 | 86-60 |
| Aminopyrine | 88150-42-9 | 900 | Bromhexine | 22-6 | 496-67-31200 |
| Aminotadalafil | 26787-78-0 | 900 | Bromopride | 1083-57-4 | 60 |
| Amitriptyline | 300-62-9 | 69-750 | Brompheniramine | 2438-72-4 | 1800 |
| Amlodipine | 53-4 | 58-00-4-300 | Bromvalerylurea | 36505-84-7 | 1950 |
| Amoxicillin | 50-78-2 | 4320 | Bucetin | 107080-63-7 | 600 |
| Amphetamine | 68844-77-9 | 375 | Bufexamac | 58-08-2 | 54-30-81650 |
| Ampicillin | 29122-68-7 | 2700 | Buspiron | 298-46-4 | 77-23-3600 |
| Apomorphine | 134523-00-5 | 600 | Butropium | 6 | 22232-54-83000 |
| Aspirin | 51-55-8 | 600 | Caffeine | 486-16-8 | 600 |
| Astemizole | 330784-47-9 | 150 | Camylofine | 944241-52-5 | 3000 |
| Atenolol | 1134-47-0 | 300 | Carbamazepine | 78-44-4 | 72956-3600 |
| Atorvastatin | 57-44-3 | 420 | Carbetapentane | 09-3 | 42540-40-150 |
| Atropine | 86541-75-5 | 150 | Carbimazole | 9 | 600 |
| Avanafil | 2156-27-6 | 600 | Carbinoxamine | | 1650 |
| Baclofen | | 300 | Carbodenafil | | 1500 |
| Barbital | | 750 | Carisoprodol | | 375 |
| Benazepril | | 450 | Carvedilol | | 2400 |
| Benproperine | | 600 | Cefamandole nafate | | 150 |

This document is issued by the Company subject to its General Conditions of Service accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained here on reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 30 days only.

Appendix

365 Chemicals for Clinical Use Test Items & LOD List :

Unit:ppm(µg/g)

| Test Item | CAS NO. | LOD | Test Item | CAS NO. | LOD |
|------------------------|-------------|------|-------------------------|-------------|------|
| Cefazolin | 25953-19-9 | 1050 | Cloperastine | 3703-76-2 | 1500 |
| Cefoperazone dihydrate | 113826-44-1 | 300 | Clotrimazole | 23593-75-1 | 3000 |
| Cefotaxime | 63527-52-6 | 150 | Cloxacillin Sodium | 7081-44-9 | 4770 |
| Ceftriaxone | 73384-59-5 | 4224 | Clozapine | 5786-21-0 | 600 |
| Celecoxib | 169590-42-5 | 900 | Cocaine | 50-36-2 | 750 |
| Cephalexin | 15686-71-2 | 75 | Colchicine | 64-86-8 | 750 |
| Cephradine | 38821-53-3 | 81 | Cortisone | 53-06-5 | 750 |
| Cetilistat | 282526-98-1 | 1500 | Cortisone acetate | 50-04-4 | 3600 |
| Cetirizine | 83881-51-0 | 159 | Cyproheptadine | 129-03-3 | 1500 |
| Chloramphenicol | 56-75-7 | 1200 | Desacetyl bisacodyl | 603-41-8 | 600 |
| Chlordiazepoxide | 58-25-3 | 300 | Desacetyl diltiazem | 42399-40-6 | 60 |
| Chlorhexidine | 55-56-1 | 2400 | Dexamethasone | 50-02-2 | 1200 |
| Chlormezanone | 80-77-3 | 60 | Dexamethasone phosphate | 312-93-6 | 900 |
| Chloropretadalafil | 171489-59-1 | 1500 | Dextromethorphan | 125-71-3 | 1500 |
| Chlorothiazide | 58-94-6 | 750 | Diazepam | 439-14-5 | 300 |
| Chlorpheniramine | 113-92-8 | 1200 | Dibucaine | 85-79-0 | 450 |
| Chlorpromazine | 50-53-3 | 300 | Diclofenac | 15307-86-5 | 600 |
| Chlorpropamide | 94-20-2 | 600 | Dicyclomine | 77-19-0 | 375 |
| Chlortetracycline | 57-62-5 | 600 | Diethylpropion | 39648-50-5 | 450 |
| Chlorzoxazone | 95-25-0 | 1050 | Diethylstilbestrol | 56-53-1 | 600 |
| Cimetidine | 51481-61-9 | 1500 | Difloxacin | 98106-17-3 | 3000 |
| Cinnarizine | 298-57-7 | 600 | Digitoxin | 71-63-6 | 450 |
| Ciprofloxacin(CFA) | 85721-33-1 | 240 | Dihydroergotamine | 511-12-6 | 150 |
| Clenbuterol | 21898-19-1 | 900 | Diltiazem | 42399-41-7 | 300 |
| Clindamycin HCl | 21462-39-5 | 456 | Dimenhydrinate | 523-87-5 | 150 |
| Clindamycin phosphate | 24729-96-2 | 150 | Dimethylsildenafil | 496835-35-9 | 3000 |
| Clobenzorex | 13364-32-4 | 375 | Dimetridazole | 551-92-8 | 150 |
| Clobetasol Propionate | 25122-46-7 | 2400 | Diphenhydramine | 58-73-1 | 375 |
| Clofibrate | 637-07-0 | 1500 | Diphenylhydantoin | 57-41-0 | 150 |
| Clonazepam | 1622-61-3 | 150 | Diprophylline | 479-18-5 | 900 |
| Clonidine | 4205-90-7 | 300 | Dipyridamole | 58-32-2 | 450 |

This document is issued by the Company subject to its General Conditions of Service accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained here on reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 30 days only.

Appendix

365 Chemicals for Clinical Use Test Items & LOD List :

Unit:ppm(µg/g)

| Test Item | CAS NO. | LOD | Test Item | CAS NO. | LOD |
|-------------------------------|--------------|------|---------------------------|-------------|-------|
| Dipyron | 68- 89-3 | 600 | Fluocinonide Fluoxetine | 356-12-7 | 3600 |
| Dithio-desmethyl-carbodenafil | 1333233-46-7 | 1500 | Fluoxymesterone | 54910-89-3 | 1200 |
| Doxazosin | 74191-85-8 | 2400 | Flurbiprofen Fluvastatin | 76-43-7 | 600 |
| Doxycycline | 564-25-0 | 576 | Furosemide Gemfibrozil | 5104-49-4 | 150 |
| Doxylamine | 469-21-6 | 60 | Gendenafl Glibenclamide | 93957-54-1 | 1200 |
| Dyclonine Hydrochloride | 536-43-6 | 3600 | Glimepiride Glipizide | 54-31-9 | 600 |
| Econazole | 27220-47-9 | 150 | Glycopyrronium | 25812-30-0 | 4500 |
| Enrofloxacin | 93106-60-6 | 3090 | Griseofulvin Guaifenesin | 147676-66-2 | 3000 |
| Eprazinone | 10402-90-1 | 300 | Haloperidol Homatropine | 10238-21-8 | 4800 |
| Erythromycin | 114-07-8 | 240 | Homosildenafil | 93479-97-1 | 2400 |
| Estazolam | 29975-16-4 | 60 | Hydralazine | 29094-61-9 | 3000 |
| Estradiol | 50- 28-2 | 1200 | Hydrochlorothiazide | 740028-90-4 | 900 |
| Estradiol benzoate | 50- 50-0 | 600 | Hydrocortisone | 126-07-8 | 450 |
| Estriol | 50- 27-1 | 60 | Hydroxyacetildenafil | 93-14-1 | 2400 |
| Estrone | 53- 16-7 | 30 | Hydroxyhomosildenafil | 52-86-8 | 1620 |
| Ethinyl estradiol | 57- 63-6 | 30 | Hydroxythiohomosildenafil | 87-00-3 | 150 |
| Ethisterone | 434-03-7 | 600 | Hydroxyvardenafl | 642928-07-2 | 1350 |
| Ethoxybenzamide | 938-73-8 | 600 | Hydroxyzine | 86-54-4 | 450 |
| Ethylestrenol | 965-90-2 | 30 | Ibuprofen | 58-93-5 | 600 |
| Etodolac | 41340-25-4 | 600 | Imidazosagatriazinone | 50-23-7 | 750 |
| Etofibrate | 31637-97-5 | 3000 | Imipramine | 147676-56-0 | 600 |
| Famotidine | 76824-35-6 | 750 | Indapamide | 139755-85-4 | 1200 |
| Fenbufen | 36330-85-5 | 1875 | Indomethacin Isoniazid | 479073-82-0 | 1650 |
| Fenfluramine | 458-24-2 | 375 | | 224785-98-2 | 1500 |
| Fenofibrate | 49562-28-9 | 150 | | 2192-20-3 | 900 |
| Fenoterol | 13392-18-2 | 750 | | 15687-27-1 | 1200 |
| Finasteride (Proscar) | 98319-26-7 | 3000 | | 139756-21-1 | 1200 |
| Flavoxate | 15301-69-6 | 900 | | 50-49-7 | 60 |
| Elibanserin | 167933-07-5 | 3600 | | 26807-65-8 | 2400 |
| Fluconazole | 86386-73-4 | 480 | | 53-86-1 | 1200 |
| Flufenamic acid | 530-78-9 | 4050 | | 54-85-3 | 302.4 |

This document is issued by the Company subject to its General Conditions of Service accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained here on reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 30 days only.

Appendix

365 Chemicals for Clinical Use Test Items & LOD List :

Unit:ppm(µg/g)

| Test Item | CAS NO. | LOD | Test Item | CAS NO. | LOD |
|---------------------------|-------------|------|---------------------------|-------------|------|
| Ketoconazole | 65277-42-1 | 300 | Metronidazole | 443-48-1 | 900 |
| Ketoprofen | 22071-15-4 | 450 | Mexiletine | 31828-71-4 | 1500 |
| Ketotifen fumarate | 34580-14-8 | 60 | Midazolam | 59467-70-8 | 60 |
| Lidocaine | 137-58-6 | 60 | Minocycline | 10118-90-8 | 750 |
| Lincomycin | 154-21-2 | 1710 | Minoxidil | 38304-91-5 | 600 |
| Liothyronine | 6893-02-3 | 3600 | Morphine | 57-27-2 | 150 |
| Lomefloxacin | 98079-51-7 | 1500 | Nalidixic acid | 389-08-2 | 300 |
| Lorazepam | 846-49-1 | 300 | Naloxone | 465-65-6 | 384 |
| Lorcaserin | 616202-92-7 | 900 | Naltrexone | 16590-41-3 | 2370 |
| Maprotiline | 10262-69-8 | 150 | Nandrolone | 434-22-0 | 750 |
| Mazindol | 22232-71-9 | 1950 | Naphazoline Hydrochloride | 835-31-4 | 300 |
| Meclizine | 569-65-3 | 60 | Naproxen | 22204-53-1 | 900 |
| Mefenamic acid | 61-68-7 | 900 | N-Desethylvardenafil | 448184-46-1 | 3000 |
| Melatonin | 73-31-4 | 1200 | N-Desmethylacetildenafil | 147676-55-9 | 3000 |
| Meloxicam | 71125-38-7 | 4500 | N-Desmethylsibutramine | 168835-59-4 | 3000 |
| Meperidine | 57-42-1 | 150 | N-Desmethylsildenafil | 139755-82-1 | 3000 |
| Mephenesin | 59-47-2 | 150 | N-Didesmethylsibutramine | 84467-54-9 | 3000 |
| Mephentermine | 100-92-5 | 240 | Neropam | 13669-70-0 | 300 |
| Meprobamate | 57-53-4 | 375 | Nicametate | 3099-52-3 | 2550 |
| Metformin | 657-24-9 | 300 | Nicotine | 54-11-5 | 60 |
| Methamphetamine | 537-46-2 | 750 | Nifedipine | 21829-25-4 | 600 |
| Methandriol | 521-10-8 | 2400 | Nifuroxazide | 965-52-6 | 540 |
| Methandrostenolone | 72-63-9 | 600 | Nitrazepam | 146-22-5 | 600 |
| Methaqualone | 72-44-6 | 900 | Nitrofurantoin | 67-20-9 | 450 |
| Metharbital | 50-11-3 | 750 | Nitrofurazone | 59-87-0 | 4410 |
| Methimazole | 60-56-0 | 300 | Noracetildenafil | 949091-38-7 | 300 |
| Methyl-DOPA Sesquihydrate | 41372-08-1 | 1620 | Noraminyopyrine | 519-98-2 | 2400 |
| Methylprednisolone | 83-43-2 | 750 | Norethisterone | 68-22-4 | 600 |
| Methyltestosterone | 58-18-4 | 600 | Norfloxacin | 70458-96-7 | 300 |
| Metoclopramide | 364-62-5 | 750 | Norfludiazepam | 2886-65-9 | 150 |
| Metoprolol | 51384-51-1 | 150 | Norgestrel | 6533-00-2 | 600 |

This document is issued by the Company subject to its General Conditions of Service accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained here on reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 30 days only.

30 Boon Lay Way, #03-01, Singapore 609957 t +65 6379 0111
SGS Testing & Control Services Singapore Pte Ltd

Co. Reg. No: 199404065N GST Reg. No: MR-8500112-9

e sgs.genlab@sgs.com www.sgs.com
Member of SGS Group

Appendix

365 Chemicals for Clinical Use Test Items & LOD List :

Unit:ppm(µg/g)

| Test Item | CAS NO. | LOD | Tes | CAS NO. | LOD |
|------------------------|-------------|------|----------------|-------------|------|
| Norneosildenafil | 371959-09-0 | 1000 | Piperidenafil | 224788-34-5 | 1500 |
| Nortadalafil Noscapine | 171596-36-4 | 1500 | Pirenzepine | 28797-61-7 | 1350 |
| Nylidrin Ofloxacin | 128-62-1 | 300 | Piroxicam | 36322-90-4 | 600 |
| Omeprazole Orlistat | 849-55-8 | 4500 | Prazosin | 19216-56-9 | 300 |
| Orphenadrine | 82419-36-1 | 1920 | Prednisolone | 50-24-8 | 1200 |
| Oxeladin Oxethazaine | 73590-58-6 | 1200 | Prednisone | 53-03-2 | 750 |
| Oxybutynin | 96829-58-2 | 375 | Prilocaine | 721-50-6 | 750 |
| Oxymetholone | 83-98-7 | 300 | Primidone | 125-33-7 | 30 |
| Oxyphenbutazone | 468-61-1 | 120 | Probenecid | 57-66-9 | 900 |
| Oxyphencyclimine | 126-27-2 | 150 | Procaine | 59-46-1 | 300 |
| Oxytetracycline (OTC) | 5633-20-5 | 4635 | Progesterone | 57-83-0 | 600 |
| Papaverine | 434-07-1 | 1050 | Promethazine | 60-87-7 | 300 |
| Pentazocine | 129-20-4 | 450 | Propafenone | 54063-53-5 | 2400 |
| Pentobarbital | 125-53-1 | 75 | Propantheline | 298-50-0 | 3000 |
| Pentoxifylline | 79-57-2 | 960 | Propranolol | 525-66-6 | 1350 |
| Phenacetin | 58-74-2 | 1560 | Propyphenazone | 479-92-5 | 3000 |
| Phenazopyridine | 359-83-1 | 30 | Quetiapine | 111974-69-7 | 2400 |
| Phenformin | 76-74-4 | 150 | Quinine | 130-95-0 | 300 |
| Phenobarbital | 6493-05-6 | 2400 | Ranitidine | 66357-59-3 | 600 |
| Phenolphthalein | 62-44-2 | 3600 | Reserpine | 50-55-5 | 1200 |
| Phentermine | 94-78-0 | 750 | Rifampin | 13292-46-1 | 120 |
| Phentolamine | 114-86-3 | 900 | Rimonabant | 168273-06-1 | 3000 |
| Phenylbutazone | 50-06-6 | 900 | Rosiglitazone | 122320-73-4 | 3000 |
| Phenylephrine | 77-09-8 | 600 | Salbutamol | 18559-94-9 | 37.5 |
| Phenylpropanolamine | 122-09-8 | 1500 | Salicylamide | 65-45-2 | 600 |
| Pioglitazone | 50-60-2 | 1500 | Salicylic acid | 69-72-7 | 900 |
| Piperiacetildenafil | 50-33-9 | 750 | Santonin | 481-06-1 | 450 |
| | 59-42-7 | 2850 | Scopolamine | 6533-68-2 | 150 |
| | 14838-15-4 | 60 | Secobarbital | 76-73-3 | 900 |
| | 111025-46-8 | 1200 | Sibutramine | 106650-56-0 | 1200 |
| | 147676-50-4 | 3000 | Sildenafil | 139755-83-2 | 1200 |

This document is issued by the Company subject to its General Conditions of Service accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained here on reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 30 days only.

Appendi

365 Chemicals for Clinical Use Test Items & LOD List :

Unit:ppm(µg/g)

| Test Item | CAS NO. | LOD | Test Item | CAS NO. | LOD |
|-------------------------|--------------|------|---|-------------|------|
| Simvastatin | 79902-63-9 | 600 | Tetracycline | 60-54-8 | 750 |
| Spironolactone | 52-01-7 | 300 | Tetramethylpyrazine | | |
| Stanozolol | 10418-03-8 | 2100 | Theobromine | 1124-11-4 | 2400 |
| Strychnine | | | Theophylline | | |
| Sulfadiazine | 57-24-9 | 900 | Thiodimethylsildenafil | 83-67-0 | 600 |
| Sulfadimethoxine | 68-35-9 | 600 | Thiohomosildenafil | | |
| Sulfamerazine | 122-11-2 | 750 | Thioridazine | 58-55-9 | 600 |
| Sulfamethazine | 127-79-7 | 450 | Thiosildenafil | | |
| Sulfamethizole | 57-68-1 | 600 | Tiletamine | | |
| Sulfamethoxazole | 144-82-1 | 600 | Timolol | | |
| Sulfamethoxyipyridazine | 723-46-6 | 600 | Maleate | 856190-47-1 | 450 |
| Sulfamonomethoxine | 80-35-3 | 450 | Tinidazole | | |
| Sulfanilamide | 1220-83-3 | 4650 | Tolbutamide | | |
| Sulfapyridine | 63-74-1 | 375 | Topiramate | | |
| Sulfaquinoxaline | 144-83-2 | 2400 | Trazodone | 479073-80-8 | 450 |
| Sulfathiazole | 59-40-5 | 4740 | hydrochloride | | |
| Sulfinpyrazone | 72-14-0 | 600 | Triamcinolone | | |
| Sulfisomidine | 57-96-5 | 750 | Triamcinolone acetonide | 50-52-2 | 300 |
| Sulfisoxazole | 515-64-0 | 3000 | Triazolam | 479073-79-5 | 450 |
| Sulindac | 127-69-5 | 450 | Triazolam | | |
| Sulpiride | 38194-50-2 | 750 | Triamethoprim | 14176-49-9 | 300 |
| Synephrine | 15676-16-1 | 1140 | Triprolidine | 26921-17-5 | 150 |
| Tadalafil | | | Usnic acid | 19387-91-8 | 900 |
| Terbinafine | 94-07-5 | 450 | Vardenafil | 64-77-7 | 375 |
| Terfenadine | 171 596-29-5 | 600 | Vardenafil analogue(Molecular weight312.37) | 97240-79-4 | 450 |
| Testosterone | 91161-71-6 | 300 | Verapamil | 19794-93-5 | 3000 |
| Testosterone propionate | 50679-08-8 | 450 | Xanthinol Niacinate | | |
| Tetracaine | 58-22-0 | 600 | Yohimbine | 124-94-7 | 900 |
| | 57-85-2 | 3000 | Zolazepam HCl | 76-25-5 | 4800 |
| | 94-24-6 | 600 | Zolpidem | 28911-01-5 | 150 |
| | | | --- | 738-70-5 | 1500 |
| | | | | 486-12-4 | 60 |
| | | | | 125-46-2 | 3600 |
| | | | | 224785-90-4 | 1800 |
| | | | | 224789-21-3 | 1800 |
| | | | | 152-11-4 | 60 |
| | | | | 437-74-1 | 1050 |
| | | | | 146-48-5 | 1500 |
| | | | | 31352-82-6 | 60 |
| | | | | 82626-48-0 | 300 |
| | | | | --- | --- |

*Tested by SGS Lab (Ref: PUF23700378)

This document is issued by the Company subject to its General Conditions of Service accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained here on reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 30 days only.